# Greenwich LifeSciences (GLSI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/GLSI
## Company Profile
- Ticker: GLSI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cancer Peptide Vaccines, Immunotherapy, Tumor Synthetic Peptide Vaccines, Oncology
## Stock Data
- Close: 15.95 USD
- Market cap: 356533672.32 USD
- Last updated: 2026-09-04
## Business Overview
Greenwich LifeSciences is an immunotherapy company focused on cancer vaccines and breast-cancer treatment. Its story is built around a narrow but potentially differentiated oncology program.
## Why The Stock Is Moving

As of Sep 4, 2026, GLSI closed up 2.05% at $15.95. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Greenwich sits in specialty oncology biotechnology.

## Business Model

The company depends on clinical data, target validation, and the possibility of creating a focused cancer-immunotherapy franchise.

## Landscape Position

Greenwich is a high-catalyst oncology name whose stock is very sensitive to trial and translational outcomes.

## Future Catalysts

- Greenwich’s catalysts are its breast-cancer immunotherapy program and any update that shows the platform still has a path forward. The next development step matters because the story is still highly data-dependent.

## Recent News
- 2026-08-10 10:00 EST — [Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-extends-lock-up-of-directors-and-officers-to-january-31-2-d5042182) — Source: Greenwich LifeSciences
- 2026-07-22 10:00 EST — [Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-approval-to-expand-flamingo-01-into-the-united--ec05cb97) — Source: Greenwich LifeSciences
- 2026-07-20 10:00 EST — [Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-clinical-updates-on-flamingo-01-99f074c4) — Source: Greenwich LifeSciences
- 2026-07-16 11:30 EST — [Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-european-approval-for-combining-both-hla-popula-adf83f60) — Source: Greenwich LifeSciences
- 2026-07-09 10:00 EST — [Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-european-approval-for-use-of-commercially-manuf-3adb0b48) — Source: Greenwich LifeSciences